The Scientist Who Decided to Change the Math
In a research room at Stanford, Dr. Michelle Longmire was studying systemic sclerosis - a disease rare enough that finding two identical twins with the condition in the same city was practically impossible. She needed participants. She couldn't get them. The limitation wasn't scientific. It was logistical. People couldn't get to Stanford. So the trial crawled. And she got angry in the most productive way possible.
That particular frustration in 2015 launched Medable - now the leading agentic AI platform for clinical development, deployed across 400 trials in 70 countries, serving more than one million patients in 120 languages. The problem she hit as a researcher became the company she built as a founder.
She didn't start with a clean exit from medicine. She raised $700,000 while still finishing her residency. She hired engineers while seeing patients. She held both identities - physician and founder - until 2016, when it became obvious which one needed her full attention. "I went for it and I never looked back," she said. "I just loved that the sky was the limit - it was up to us."
"What will limit more diseases being cured is not the ability to create the compounds. It's the ability to test them."- Dr. Michelle Longmire, Co-Founder & CEO, Medable
Raised Where They Split the Atom
Los Alamos, New Mexico is not a typical childhood address. It is the birthplace of the atomic bomb, a town built around a national laboratory, where neighbors discuss isotope decay at dinner. Michelle Longmire grew up there, and the environment was not incidental to who she became.
Her grandfather contributed to hydrogen bomb development and electromagnetic pulse theory. Her mother is a radiochemist specializing in plutonium. Her father was a molecular biologist who worked on the Human Genome Project - and then, in a move only a scientist would attempt, taught himself falconry and developed the first genetic assay to determine bird sex, enabling Whooping Crane breeding programs. A family where solving a problem means building the tool that didn't exist yet.
She grew up understanding that innovation isn't a career category - it's a reflex. The family described their culture as "all about innovation and discovery." That framing stuck.
The Late Starter
Started playing soccer at 14, three years after most competitive players. Trained 3+ hours daily against every skeptic. Earned a Division I scholarship to University of New Mexico within three years.
The Reluctant Physician
A Rhodes Scholarship finalist who took the MCAT on a friend's suggestion. Discovered that dermatology was "an access point to the broader story on human health and disease." Went deeper than anyone expected.
The Builder
Raised $700K as a resident. Hired engineers. Pivoted when the first product stalled. Refused every no. Built a $2.1 billion platform from the ground up. The fearlessness is the feature, not the background.
Medable: The Platform Built from a Clinical Hallway Insight
Medable launched in 2015 as a HIPAA-compliant mobile platform for patient and enterprise healthcare access. The pitch was clean; the developer adoption was not. The initial product struggled. Longmire and her team pivoted toward clinical trial applications - which is when things got interesting.
Bob Duggan, a significant investor in biotech, saw something worth betting $3 million on. Tyler Pugsley, recruited from IBM, drove biopharma partnerships. The company grew methodically until COVID-19 compressed five years of market evolution into five months.
"Everything just started blowing up," Longmire said. "People heard we had a remote clinical trial capability and asked us to have it operational two days later." By the time pharma companies realized they needed decentralized trial infrastructure, Medable had already built it. Between 2019 and 2020, revenue grew 300 percent. Employee count went from 100 to 400. Net revenue retention hit 125 percent.
In October 2021, Medable closed a $304 million Series D at a $2.1 billion valuation, co-led by Blackstone Growth, GSR Ventures, and Tiger Global. Total venture capital raised crossed $500 million. The platform was now in 60 countries across 150+ trials. The insight from that Stanford research room had become infrastructure for the global drug development industry.
"If you take the current timeline and then the biggest problem of human suffering and disease, we're on a 200-year path, at best, to cure human illness."- Dr. Michelle Longmire
Agentic AI and the Next Phase
Medable's current work centers on what the company calls Agent Studio - a platform capability where AI agents automatically handle the repetitive, compliance-driven work that clogs clinical operations: sorting documents, checking submissions, filing forms, flagging deviations. Human oversight stays in the loop. The machine handles the volume.
Longmire's thesis is specific: approximately 60 percent of clinical trials fail due to insufficient patient enrollment. The bottleneck isn't science - it's logistics, access, and process friction. Agentic AI can attack all three simultaneously. The goal, as she frames it, is to increase the number of approved drugs per year by tenfold - without compromising safety or efficacy.
In May 2026, she was named one of three international guest speakers at Japan's Ubie Pharma Summit - the country's largest pharmaceutical conference - sharing the stage with leaders from Google Health and Mayo Clinic Platform. Medable's platform had by then been deployed in approximately 400 trials across 70 countries. The scale made the case without a slide deck.
"I learned a lot of the key qualities of being a CEO from team sports and my experience conducting research at Stanford. I truly believe all extraordinary work is achieved by empowering your team."
What She Has Built and Won
The Long Arc
ALAMOS